Since the publication of the data regarding cyclic dosing from St. George’s University by Liu, et. al in 2016 the question of continuous dosing of LDN versus cyclic dosing has been posed.

In this presentation Dr. Anderson will discuss the cell and tumor biology – pharmacology interface where this idea comes from and develop the concept using new immunobiology data around LDN. He will share dose strategies and clinical applications.